Article Contents ::
- 1 The Brand Name IMMUPRINE Has Generic Salt :: Azathioprine
- 2 IMMUPRINE Is From Company Csc Ph. Priced :: Rs. N.I.
- 3 IMMUPRINE have Azathioprine is comes under Sub class Immunuosuppressants of Main Class Immunology , Allergy
- 4 Main Medicine Class:: Immunology , Allergy Sub Medicine Class :: Immunuosuppressants
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name IMMUPRINE Has Generic Salt :: Azathioprine
IMMUPRINE Is From Company Csc Ph. Priced :: Rs. N.I.
IMMUPRINE have Azathioprine is comes under Sub class Immunuosuppressants of Main Class Immunology , Allergy
Main Medicine Class:: Immunology , Allergy Sub Medicine Class :: Immunuosuppressants
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Rheumatoid arthritis, Prevention of rejection in organ and tissue transplantation, Auto-immune diseases, Renal homotransplantation
Drug Dose ::
Adult: PO Rheumatoid arthritis Initial: 1 mg/kg/day for 6-8 wk. May adjust dose gradually to 2.5 mg/kg/day if needed. Prevention of rejection in organ and tissue transplantation 1-5 mg/kg/day. Auto-immune diseases 1-3 mg/kg/day.
Hypersensitivity; previous treatment with alkylating agents; pregnancy, lactation.
Drug Precautions ::
Increased risk of serious infections and neoplasia in chronic immunosuppression; leucopenia, thrombocytopenia, renal or hepatic impairment. Increased risk of haematologic toxicity in patients with thiopurine methyltransferase deficiency. Monitor CBC (including platelet count) wkly during 1st mth, twice mthly for 2nd and 3rd mth, then mthly; monitor more frequently if there are dosage adjustments. Monitor LFT periodically; discontinue treatment if jaundice occurs. Reduce dose promptly or withdraw drug temporary if there is rapid decrease/persistently low WBC or signs of bone marrow depression. Dose reduction may be necessary in patients with reduced TPMT (thiopurine methyltransferase) activity.
Drug Side Effects ::
Fever, chills; bone marrow depression characterised by leucopenia, thrombocytopenia or anaemia; anorexia, nausea, diarrhoea; arthralgias; secondary infections; hepatotoxicity, rash, alopoecia. Potentially Fatal: Myelosuppression, mutagenicity and carcinogenicity; veno-occlussive liver disease.
Pregnancy category ::
Drug Mode of Action ::
Azathioprine is an imidazolyl derivative of mercaptopurine, which inhibits DNA, RNA and protein synthesis and antagonises purine synthesis. It also inhibits mitosis and interferes with cellular metabolism of susceptible organisms. Azathioprine inj should be converted to oral therapy as soon as the drug can be tolerated.
Drug Interactions ::
Increased risk of haematotoxicity with aminosalicylates, drugs that affect myelopoesis e.g. co-trimoxazole or trimethoprim. Increased risk of infections with intra-uterine devices and live vaccines. Increased risk of leucopenia with ACE inhibitors. Concurrent use may reduce the anticoagulant effect of vitamin K antagonists e.g. warfarin. Increased risk of myelosuppressive effects when used with drugs that inhibit TPMT (thiopurine methyltransferase) or xanthine oxidase e.g. olsalazine, allopurinol. Potentially Fatal: Increased risk of serious haematotoxicity or hepatotoxicity with leflunomide. Increased risk of bone marrow suppression with mycophenolate mofetil. Increased risk of infections and malignancies with efalizumab.